The Christchurch variant (R136S) of the APOE3 can provide resistance to AD pathology and symptoms, likely due to its reduced interactions with heparan sulfate proteoglycans (HSPG), ubiquitous cell surface and extracellular matrix components that facilitate Aβ aggregation, cellular internalization, and tau spreading [156]. This evidence concerns the gene MAPT and Alzheimer disease.